Results from TALAPRO-2: increased survival in metastatic castration resistant prostate cancer beyond HRR mutations (BRCA, ATM,...)
Trial results are from the last year, but based on these results, they are trying to push this combo to be used also when no HRR mutation is present:
"In the final rPFS analysis, TALZENNA plus XTANDI reduced the risk of disease progression or death by 37% versus placebo plus XTANDI (Hazard Ratio [HR
Trial results are from the last year, but based on these results, they are trying to push this combo to be used also when no HRR mutation is present:
"In the final rPFS analysis, TALZENNA plus XTANDI reduced the risk of disease progression or death by 37% versus placebo plus XTANDI (Hazard Ratio [HR